WBP3425 / Wuxi Biocity - LARVOL DELTA

The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment (IASLC-WCLC 2024) - "Here, we propose a combinational therapy with Tucidinostat (HDAC inhibitor) and WBP3425 (4-1BB Agonist) to target resistant tumors and remodel the tumor microenvironment. Comparatively, Mono.mac in the Tri group upregulated pathways related to antigen processing and presentation, antitumor (AT) responses, and macrophage recruitment to the tumor, while downregulating angiogenesis pathways (Ang) as demonstrated in Figure 1G. Conclusions : The additional combination of WBP3425 and Tucidnostat with BC3448 demonstrated a synergistic efficacy to Osimertinib-resistant tumors via a multidimensional reshaping of the microenvironment, potentially offering a comprehensive approach to combat NSCLC resistance."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • EGFR • FCER1G